Method and apparatus for neuromodulation and physiologic modulation for the treatment of metabolic and neuropsychiatric disease
First Claim
1. A method for treating a medical condition comprising:
- modulating the sympathetic nervous system, said modulating comprising delivering a signal using a neuromodulator which activates the splanchnic nerve to induce weight loss.
2 Assignments
0 Petitions
Accused Products
Abstract
A method and apparatus for physiological modulation, including neural and gastrointestinal modulation, for the purposes of treating several disorders, including obesity, depression, epilepsy, and diabetes. This includes chronically implanted neural and neuromuscular modulators, used to modulate the afferent neurons of the sympathetic nervous system to induce satiety. Furthermore, this includes neuromuscular stimulation of the stomach to effect baseline and intermittent smooth muscle contraction to increase gastric intraluminal pressure, which induces satiety, and stimulate sympathetic afferent fibers, including those in the sympathetic trunk, splanchnic nerves, and greater curvature of the stomach, to augment the perception of satiety.
-
Citations
234 Claims
-
1. A method for treating a medical condition comprising:
modulating the sympathetic nervous system, said modulating comprising delivering a signal using a neuromodulator which activates the splanchnic nerve to induce weight loss. - View Dependent Claims (2, 3, 4, 5, 6, 7)
-
8. A method for treating a medical condition comprising:
-
modulating the sympathetic nervous system, said modulating comprising delivering a signal using a neuromodulator to activate a splanchnic nerve, said splanchnic nerve comprising at least one of the superior splanchnic nerve, inferior splanchnic nerve, and other neural structure, said activating inducing physiological effects, and wherein said physiologic effects include change in plasma glucose levels.
-
-
9. A method for treating a medical condition comprising:
-
modulating the sympathetic nervous system, said modulating comprising delivering a signal using a neuromodulator to activate a splanchnic nerve, said splanchnic nerve comprising at least one of the superior splanchnic nerve, inferior splanchnic nerve, and other neural structure, said activating inducing physiological effects, and wherein said physiologic effects include change in plasma insulin levels.
-
-
10. A method for treating a medical condition comprising:
-
modulating the sympathetic nervous system, said modulating comprising delivering a signal using a neuromodulator to activate a splanchnic nerve, said splanchnic nerve comprising at least one of the superior splanchnic nerve, inferior splanchnic nerve, and other neural structure, said activating inducing physiological effects, and wherein said physiologic effects include change in appetite.
-
-
11. A method for treating a medical condition comprising:
-
modulating the sympathetic nervous system, said modulating comprising delivering a signal to activate a splanchnic nerve, said splanchnic nerve comprising at least one of the superior splanchnic nerve, inferior splanchnic nerve, and other neural structure, and wherein said activating the splanchnic nerve comprises; activating the splanchnic nerve to increase plasma glucose levels, thereby reducing appetite; and activating the splanchnic nerve to increase plasma catecholamine levels, thereby increasing energy expenditure.
-
-
12. A method for treating a medical condition comprising:
modulating the sympathetic nervous system, said modulating comprising delivering a signal using a neuromodulator to activate a splanchnic nerve to reduce insulin secretion.
-
13. A method for activating the splanchnic nerve to treat obesity comprising:
-
applying a current pulse to the splanchnic nerve, and selecting the duration of said current pulse to be no greater than the chronaxie of the splanchnic nerve.
-
-
14. A method for activating the splanchnic nerve to treat obesity comprising:
-
applying a current pulse to the splanchnic nerve, and selecting the duration of said current pulse to be within the range of 1 microsecond and 500 milliseconds.
-
-
15. A method for activating the splanchnic nerve to treat obesity comprising:
applying a current pulse to the splanchnic nerve, wherein said current pulse is biphasic.
-
16. A method for activating the splanchnic nerve to treat obesity comprising:
-
applying a current pulse to the splanchnic nerve, and selecting the amplitude of said current pulse to be within the range of 1 microamp and 1000 milliamps.
-
-
17. A method for activating the splanchnic nerve to treat obesity comprising:
-
applying a current pulse to the splanchnic nerve, and selecting the interpulse interval to be within the range of 1 microsecond and 1000 milliseconds.
-
-
18. A method for activating the splanchnic nerve to treat obesity comprising:
-
applying a current pulse to the splanchnic nerve, and selecting the duration of said current pulse to be between 100 microseconds and 400 microseconds.
-
-
19. A method for activating the splanchnic nerve to treat obesity comprising:
-
implanting a pulse generator within a patient, said pulse generator having programmable treatment parameters, programming said treatment parameters to induce satiety, and applying a current pulse to the splanchnic nerve with said pulse generator.
-
-
20. A method for treating a medical condition comprising:
modulating the sympathetic nervous system to treat obesity, wherein obesity is treated using unipolar stimulation of a splanchnic nerve. - View Dependent Claims (21, 22, 23, 24, 25)
-
26. A method for treating a medical condition comprising:
modulating the sympathetic nervous system to treat obesity, wherein obesity is treated using bipolar stimulation of a splanchnic nerve.
- 27. A method for treating a user comprising delivering energy using a neuromodulator in communication with at least a portion of the intermediolateral nucleus at levels T1-T9.
- 38. A method for treating a user comprising delivering energy using a neuromodulator in communication with projections from the intermediolateral nucleus at levels T1-T9.
- 49. A method for treating a user comprising delivering energy using a neuromodulator in communication with projections to the intermediolateral nucleus.
- 81. A method for treating a user comprising applying an electrical signal to the intermediolateral nucleus, wherein duration of said signal is greater than 10 seconds per day.
-
102. A method for activating the intermediolateral nucleus to treat a user comprising:
-
applying an electrical signal to the intermediolateral nucleus; and selecting stimulation parameters which cause weight reduction. - View Dependent Claims (113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 158, 159, 160, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 191, 193, 195, 197, 199, 201, 203, 205, 207, 209, 211, 213, 232, 234)
-
-
103. A method for activating the intermediolateral nucleus to treat a user comprising:
-
applying an electrical signal to the intermediolateral nucleus; and selecting stimulation parameters which cause appetite reduction.
-
-
104. A method for activating the intermediolateral nucleus to treat a user comprising:
-
applying an electrical signal to the intermediolateral nucleus; and selecting stimulation parameters which induce satiety.
-
-
105. A method for activating the intermediolateral nucleus to treat a user comprising:
-
applying an electrical signal to the intermediolateral nucleus; and selecting stimulation parameters which cause increase in metabolism.
-
-
106. A method for activating the intermediolateral nucleus to treat a user comprising:
-
selecting a user in whom body weight is to be reduced; and applying an electrical signal to the intermediolateral nucleus. - View Dependent Claims (107, 108)
-
-
109. A method for activating the intermediolateral nucleus to treat a user comprising:
-
selecting a user with a body weight above normal; and applying an electrical signal to the intermediolateral nucleus. - View Dependent Claims (110, 111, 112)
-
-
161. The method recited in claims any one of 41-53, further comprising:
-
A. implanting at least one electrode such that it is in communication with afferent pathways comprising the intermediolateral nucleus; and B. implanting at least one electrode such that it is in communication with efferent pathways comprising the spinal cord.
-
-
214. A method for reducing body weight in a user comprising:
-
(A) selecting a user of body weight control; (B) positioning a neuromodulator in communication with at least a component of the intermediolateral nucleus; and (C) modulating sympathetic activity for control of body weight. - View Dependent Claims (215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230)
-
Specification